Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes
Breast MRI
Subtyping
DOI:
10.1007/s11307-019-01383-w
Publication Date:
2019-06-17T20:37:42Z
AUTHORS (12)
ABSTRACT
To compare annotation segmentation approaches and to assess the value of radiomics analysis applied diffusion-weighted imaging (DWI) for evaluation breast cancer receptor status molecular subtyping. In this IRB-approved HIPAA-compliant retrospective study, 91 patients with treatment-naïve malignancies proven by image-guided biopsy, (luminal A, n = 49; luminal B, 8; human epidermal growth factor 2 [HER2]-enriched, 11; triple negative [TN], 23) underwent multiparametric magnetic resonance (MRI) at 3 T dynamic contrast-enhanced MRI, T2-weighted DW imaging. Lesions were manually segmented on high b-value images ROIS propagated apparent diffusion coefficient (ADC) maps. addition in a subgroup (n 79) where lesions discernable ADC maps alone, these also directly there. derive signatures, following features extracted analyzed: first-order histogram (HIS), co-occurrence matrix (COM), run-length (RLM), absolute gradient, autoregressive model (ARM), discrete Haar wavelet transform (WAV), lesion geometry. Fisher, probability error average correlation, mutual information coefficients used feature selection. Linear discriminant followed k-nearest neighbor classification leave-one-out cross-validation was pairwise differentiation Histopathologic results considered gold standard. For that DWI ROIs accuracies > 90% obtained: B vs. HER2-enriched, 94.7 % (based COM features); others, 92.3 (COM, HIS); HER2-enriched 90.1 (RLM, COM). maps, better achieved yielding accuracies: 100 WAV); A 91.5 91.1 (WAV, ARM, Radiomic signatures from mapping allows subtyping diagnostic accuracy. Better obtained when tumor segmentations could be performed
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (65)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....